Have a feature idea you'd love to see implemented?
Let us know!
UTHR UNITED THERAPEUTICS Corp
Price (delayed)
$367.36
Market cap
$16.4B
P/E Ratio
15.11
Dividend/share
N/A
EPS
$24.31
Enterprise value
$15.25B
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and
Highlights
The debt has plunged by 50% YoY and by 20% from the previous quarter
The company's EPS rose by 26% YoY and by 5% QoQ
The stock's P/E is 23% above its last 4 quarters average of 12.3 and 9% above its 5-year quarterly average of 13.8
Key stats
What are the main financial stats of UTHR
Market
Valuations
Earnings
Shares outstanding
44.64M
Market cap
$16.4B
Enterprise value
$15.25B
Price to earnings (P/E)
15.11
Price to book (P/B)
2.68
Price to sales (P/S)
5.94
EV/EBIT
10.25
EV/EBITDA
9.81
EV/Sales
5.53
Revenue
$2.76B
EBIT
$1.49B
EBITDA
$1.55B
Free cash flow
$898.1M
Per share
Balance sheet
Liquidity
EPS
$24.31
Free cash flow per share
$20.14
Book value per share
$137.13
Revenue per share
$61.8
TBVPS
$157.2
Total assets
$7.12B
Total liabilities
$1.02B
Debt
$400M
Equity
$6.1B
Working capital
$3.13B
Debt to equity
0.07
Current ratio
4.58
Quick ratio
4.2
Net debt/EBITDA
-0.74
Margins
Efficiency
Dividend
EBITDA margin
56.4%
Gross margin
88.9%
Net margin
40.3%
Operating margin
46.4%
Return on assets
16.2%
Return on equity
19.2%
Return on invested capital
29%
Return on capital employed
23.8%
Return on sales
54%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UTHR stock price
How has the UNITED THERAPEUTICS stock price performed over time
Intraday
0.83%
1 week
-4.9%
1 month
-0.87%
1 year
59.42%
YTD
67.07%
QTD
2.51%
Financial performance
How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$2.76B
Gross profit
$2.45B
Operating income
$1.28B
Net income
$1.11B
Gross margin
88.9%
Net margin
40.3%
The company's gross profit rose by 25% YoY and by 5% QoQ
The company's revenue rose by 25% YoY and by 5% QoQ
UNITED THERAPEUTICS's net income has increased by 23% YoY and by 3.9% QoQ
The operating income has grown by 16% YoY
Growth
What is UNITED THERAPEUTICS's growth rate over time
Valuation
What is UNITED THERAPEUTICS stock price valuation
P/E
15.11
P/B
2.68
P/S
5.94
EV/EBIT
10.25
EV/EBITDA
9.81
EV/Sales
5.53
The company's EPS rose by 26% YoY and by 5% QoQ
The stock's P/E is 23% above its last 4 quarters average of 12.3 and 9% above its 5-year quarterly average of 13.8
UTHR's price to book (P/B) is 34% higher than its 5-year quarterly average of 2.0 and 22% higher than its last 4 quarters average of 2.2
The equity has increased by 7% since the previous quarter and by 7% year-on-year
The stock's P/S is 26% above its 5-year quarterly average of 4.7 and 19% above its last 4 quarters average of 5.0
The company's revenue rose by 25% YoY and by 5% QoQ
Efficiency
How efficient is UNITED THERAPEUTICS business performance
The ROIC has grown by 37% YoY and by 7% from the previous quarter
UNITED THERAPEUTICS's return on assets has increased by 17% YoY and by 3.8% QoQ
The ROE has grown by 12% YoY and by 2.1% from the previous quarter
The company's return on sales fell by 3.1% QoQ
Dividends
What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UTHR.
Financial health
How did UNITED THERAPEUTICS financials performed over time
The company's total liabilities fell by 22% YoY
The quick ratio has increased by 7% since the previous quarter
The debt is 93% less than the equity
UNITED THERAPEUTICS's debt to equity has shrunk by 50% YoY and by 22% QoQ
The debt has plunged by 50% YoY and by 20% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.